| Title |
Anticholinergic Drugs for Overactive Bladder in Frail Older Patients: The Case Against
|
|---|---|
| Published in |
Drugs & Aging, August 2018
|
| DOI | 10.1007/s40266-018-0575-x |
| Pubmed ID | |
| Authors |
Henry J. Woodford |
| Abstract |
Urinary incontinence (UI) is a common and disabling problem among older people. Anticholinergic drugs (ADs) are a pharmacological option recommended for overactive bladder or mixed UI when non-pharmacological approaches have failed. However, UI is a more prevalent and complex condition in frail older people and to simply assume that AD actions are the same across all age groups would be wrong. This article reviews evidence for the efficacy and safety of these drugs, especially when prescribed for frail older people. Although ADs have a small but statistically significant benefit for UI in non-frail people, the vast majority choose to discontinue treatment because they feel that the beneficial effects do not outweigh the burden of taking the medication. Not only are the most frail older people more likely to experience adverse effects but there is also no evidence that these drugs are effective for UI. In addition, there is a mounting body of evidence that they impair cognitive function. The continued use of ADs in frail older people simply does not hold water. |
X Demographics
The data shown below were collected from the profiles of 19 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 9 | 47% |
| Ireland | 1 | 5% |
| Malaysia | 1 | 5% |
| Australia | 1 | 5% |
| United States | 1 | 5% |
| Saudi Arabia | 1 | 5% |
| Unknown | 5 | 26% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 10 | 53% |
| Practitioners (doctors, other healthcare professionals) | 6 | 32% |
| Scientists | 3 | 16% |
Mendeley readers
The data shown below were compiled from readership statistics for 30 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 30 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 5 | 17% |
| Researcher | 5 | 17% |
| Student > Master | 4 | 13% |
| Student > Ph. D. Student | 2 | 7% |
| Student > Postgraduate | 2 | 7% |
| Other | 0 | 0% |
| Unknown | 12 | 40% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 8 | 27% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 13% |
| Nursing and Health Professions | 2 | 7% |
| Economics, Econometrics and Finance | 1 | 3% |
| Social Sciences | 1 | 3% |
| Other | 1 | 3% |
| Unknown | 13 | 43% |
Attention Score in Context
This research output has an Altmetric Attention Score of 12. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 October 2023.
All research outputs
#3,120,745
of 25,728,855 outputs
Outputs from Drugs & Aging
#198
of 1,303 outputs
Outputs of similar age
#58,809
of 342,279 outputs
Outputs of similar age from Drugs & Aging
#3
of 24 outputs
Altmetric has tracked 25,728,855 research outputs across all sources so far. Compared to these this one has done well and is in the 87th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,303 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.3. This one has done well, scoring higher than 84% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 342,279 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 82% of its contemporaries.
We're also able to compare this research output to 24 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 87% of its contemporaries.